• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

将 SARS-CoV-2 传播的流行病学模型中的假阴性检测结果纳入并与血清阳性率估计值相协调。

Incorporating false negative tests in epidemiological models for SARS-CoV-2 transmission and reconciling with seroprevalence estimates.

机构信息

Department of Biostatistics, School of Public Health, University of Michigan, 1420 Washington Heights, Ann Arbor, MI, 48109-2029, USA.

Indian Statistical Institute, Kolkata, West Bengal, 700108, India.

出版信息

Sci Rep. 2021 May 7;11(1):9748. doi: 10.1038/s41598-021-89127-1.

DOI:10.1038/s41598-021-89127-1
PMID:33963259
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8105357/
Abstract

Susceptible-Exposed-Infected-Removed (SEIR)-type epidemiologic models, modeling unascertained infections latently, can predict unreported cases and deaths assuming perfect testing. We apply a method we developed to account for the high false negative rates of diagnostic RT-PCR tests for detecting an active SARS-CoV-2 infection in a classic SEIR model. The number of unascertained cases and false negatives being unobservable in a real study, population-based serosurveys can help validate model projections. Applying our method to training data from Delhi, India, during March 15-June 30, 2020, we estimate the underreporting factor for cases at 34-53 (deaths: 8-13) on July 10, 2020, largely consistent with the findings of the first round of serosurveys for Delhi (done during June 27-July 10, 2020) with an estimated 22.86% IgG antibody prevalence, yielding estimated underreporting factors of 30-42 for cases. Together, these imply approximately 96-98% cases in Delhi remained unreported (July 10, 2020). Updated calculations using training data during March 15-December 31, 2020 yield estimated underreporting factor for cases at 13-22 (deaths: 3-7) on January 23, 2021, which are again consistent with the latest (fifth) round of serosurveys for Delhi (done during January 15-23, 2021) with an estimated 56.13% IgG antibody prevalence, yielding an estimated range for the underreporting factor for cases at 17-21. Together, these updated estimates imply approximately 92-96% cases in Delhi remained unreported (January 23, 2021). Such model-based estimates, updated with latest data, provide a viable alternative to repeated resource-intensive serosurveys for tracking unreported cases and deaths and gauging the true extent of the pandemic.

摘要

易感性-暴露-感染-移除(SEIR)型流行病学模型,对潜伏性未确诊感染进行建模,可以在假设检测完美的情况下预测未报告的病例和死亡。我们应用了一种我们开发的方法,该方法考虑了用于检测活跃 SARS-CoV-2 感染的诊断 RT-PCR 检测的高假阴性率,以应用于经典 SEIR 模型。在实际研究中,未确诊病例和假阴性的数量是不可观察的,基于人群的血清学调查可以帮助验证模型预测。我们将该方法应用于 2020 年 3 月 15 日至 6 月 30 日期间在印度德里的训练数据,我们估计 2020 年 7 月 10 日病例的漏报率为 34-53(死亡:8-13),这与德里的第一轮血清学调查(在 2020 年 6 月 27 日至 7 月 10 日期间进行)的结果基本一致,估计 IgG 抗体的流行率为 22.86%,从而得出病例的漏报率为 30-42。综合来看,这意味着德里大约有 96-98%的病例未报告(2020 年 7 月 10 日)。使用 2020 年 3 月 15 日至 12 月 31 日期间的训练数据进行的最新计算得出,2021 年 1 月 23 日病例的漏报率估计为 13-22(死亡:3-7),这与德里最新(第五轮)血清学调查(在 2021 年 1 月 15 日至 23 日期间进行)的结果基本一致,估计 IgG 抗体的流行率为 56.13%,从而得出病例漏报率的估计范围为 17-21。综合来看,这些更新后的估计表明,德里大约有 92-96%的病例未报告(2021 年 1 月 23 日)。这种基于模型的估计,使用最新数据进行更新,为追踪未报告的病例和死亡以及评估大流行的真实程度提供了一种可行的替代方法,而无需重复进行资源密集型的血清学调查。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e8b/8105357/bf17ed5a1da2/41598_2021_89127_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e8b/8105357/2dd51beb03a1/41598_2021_89127_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e8b/8105357/18655f748b5c/41598_2021_89127_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e8b/8105357/bf17ed5a1da2/41598_2021_89127_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e8b/8105357/2dd51beb03a1/41598_2021_89127_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e8b/8105357/18655f748b5c/41598_2021_89127_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e8b/8105357/bf17ed5a1da2/41598_2021_89127_Fig3_HTML.jpg

相似文献

1
Incorporating false negative tests in epidemiological models for SARS-CoV-2 transmission and reconciling with seroprevalence estimates.将 SARS-CoV-2 传播的流行病学模型中的假阴性检测结果纳入并与血清阳性率估计值相协调。
Sci Rep. 2021 May 7;11(1):9748. doi: 10.1038/s41598-021-89127-1.
2
Estimating the wave 1 and wave 2 infection fatality rates from SARS-CoV-2 in India.估算印度 SARS-CoV-2 第 1 波和第 2 波的感染病死率。
BMC Res Notes. 2021 Jul 8;14(1):262. doi: 10.1186/s13104-021-05652-2.
3
Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak-the CoNAN study.在 2019 年冠状病毒病疫情后,对一个经过全面 PCR 检测的社区使用六种不同血清学检测方法进行抗体反应的研究——CoNAN 研究。
Clin Microbiol Infect. 2021 Mar;27(3):470.e1-470.e9. doi: 10.1016/j.cmi.2020.11.009. Epub 2020 Nov 20.
4
Estimation of US SARS-CoV-2 Infections, Symptomatic Infections, Hospitalizations, and Deaths Using Seroprevalence Surveys.利用血清流行率调查估计美国 SARS-CoV-2 感染、有症状感染、住院和死亡人数。
JAMA Netw Open. 2021 Jan 4;4(1):e2033706. doi: 10.1001/jamanetworkopen.2020.33706.
5
SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.伊朗 18 个城市一般人群和高风险职业人群中 SARS-CoV-2 抗体血清流行率:一项基于人群的横断面研究。
Lancet Infect Dis. 2021 Apr;21(4):473-481. doi: 10.1016/S1473-3099(20)30858-6. Epub 2020 Dec 15.
6
SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey.2020 年 8 月至 9 月印度 SARS-CoV-2 抗体血清阳性率:第二次全国家庭血清学调查结果。
Lancet Glob Health. 2021 Mar;9(3):e257-e266. doi: 10.1016/S2214-109X(20)30544-1. Epub 2021 Jan 27.
7
Detection of SARS-CoV-2 antibodies in pediatric patients: An Iranian referral hospital-based study.在儿科患者中检测 SARS-CoV-2 抗体:一项基于伊朗转诊医院的研究。
Hum Antibodies. 2021;29(3):217-223. doi: 10.3233/HAB-210448.
8
Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.加拿大艾伯塔省 COVID-19 大流行前两波期间 SARS-CoV-2 抗体的预疫苗阳性率。
Microbiol Spectr. 2021 Sep 3;9(1):e0029121. doi: 10.1128/Spectrum.00291-21. Epub 2021 Aug 18.
9
Immunoglobin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests.免疫球蛋白 G/总抗体检测用于 SARS-CoV-2:在比利时两家肿瘤学单位的门诊患者和医护人员中进行的前瞻性队列研究,比较了三种商业检测方法。
Eur J Cancer. 2021 May;148:328-339. doi: 10.1016/j.ejca.2021.02.024. Epub 2021 Feb 27.
10
Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.塞尔维亚北部(伏伊伏丁那)针对 SARS-CoV-2 病毒的抗体血清流行率:一项连续四次的基于哨点人群的调查研究。
PLoS One. 2021 Jul 9;16(7):e0254516. doi: 10.1371/journal.pone.0254516. eCollection 2021.

引用本文的文献

1
Uncovering associations between pre-existing conditions and COVID-19 Severity: A polygenic risk score approach across three large biobanks.揭示既往疾病与 COVID-19 严重程度之间的关联:三个大型生物库的多基因风险评分方法。
PLoS Genet. 2023 Dec 19;19(12):e1010907. doi: 10.1371/journal.pgen.1010907. eCollection 2023 Dec.
2
Estimating the number of probable new SARS-CoV-2 infections among tested subjects from the number of confirmed cases.从确诊病例数估计检测对象中可能的新 SARS-CoV-2 感染人数。
BMC Med Res Methodol. 2023 Nov 17;23(1):272. doi: 10.1186/s12874-023-02077-2.
3
Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chattogram Metropolitan Area, Bangladesh.

本文引用的文献

1
Extending the susceptible-exposed-infected-removed (SEIR) model to handle the false negative rate and symptom-based administration of COVID-19 diagnostic tests: SEIR-fansy.将易感-暴露-感染-清除(SEIR)模型扩展到处理 COVID-19 诊断测试的假阴性率和基于症状的管理:SEIR-fansy。
Stat Med. 2022 Jun 15;41(13):2317-2337. doi: 10.1002/sim.9357. Epub 2022 Feb 27.
2
SARS-CoV-2 seroprevalence in a strictly-Orthodox Jewish community in the UK: A retrospective cohort study.英国一个极端正统犹太社区的新冠病毒血清流行率:一项回顾性队列研究。
Lancet Reg Health Eur. 2021 Jul;6:100127. doi: 10.1016/j.lanepe.2021.100127.
3
Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.
孟加拉国吉大港市都会区抗SARS-CoV-2抗体的血清流行率
Antibodies (Basel). 2022 Nov 7;11(4):69. doi: 10.3390/antib11040069.
4
Role of multiresolution vulnerability indices in COVID-19 spread in India: a Bayesian model-based analysis.多分辨率脆弱性指数在印度 COVID-19 传播中的作用:基于贝叶斯模型的分析。
BMJ Open. 2022 Nov 17;12(11):e056292. doi: 10.1136/bmjopen-2021-056292.
5
Modeling Global COVID-19 Dissemination Data After the Emergence of Omicron Variant Using Multipronged Approaches.采用多管齐下的方法对奥密克戎变异株出现后全球 COVID-19 传播数据进行建模。
Curr Microbiol. 2022 Aug 10;79(9):286. doi: 10.1007/s00284-022-02985-4.
6
Assessment of the fatality rate and transmissibility taking account of undetected cases during an unprecedented COVID-19 surge in Taiwan.评估在台湾前所未有的 COVID-19 疫情高峰期间考虑未检出病例的死亡率和传染性。
BMC Infect Dis. 2022 Mar 20;22(1):271. doi: 10.1186/s12879-022-07190-z.
7
Extending the susceptible-exposed-infected-removed (SEIR) model to handle the false negative rate and symptom-based administration of COVID-19 diagnostic tests: SEIR-fansy.将易感-暴露-感染-清除(SEIR)模型扩展到处理 COVID-19 诊断测试的假阴性率和基于症状的管理:SEIR-fansy。
Stat Med. 2022 Jun 15;41(13):2317-2337. doi: 10.1002/sim.9357. Epub 2022 Feb 27.
8
The coupled dynamics of information dissemination and SEIR-based epidemic spreading in multiplex networks.多重网络中信息传播与基于SEIR模型的疫情传播的耦合动力学
Physica A. 2022 Feb 15;588:126558. doi: 10.1016/j.physa.2021.126558. Epub 2021 Nov 1.
9
Estimating COVID-19‒ Related Mortality in India: An Epidemiological Challenge With Insufficient Data.估算印度新冠肺炎相关死亡率:数据不足带来的流行病学挑战
Am J Public Health. 2021 Jul;111(S2):S59-S62. doi: 10.2105/AJPH.2021.306419.
10
COVID-19 Pandemic in India: Through the Lens of Modeling.印度的 COVID-19 大流行:建模视角。
Glob Health Sci Pract. 2021 Jun 30;9(2):220-228. doi: 10.9745/GHSP-D-21-00233.
法国 SARS-CoV-2 抗体的流行率:全国血清学监测结果。
Nat Commun. 2021 May 21;12(1):3025. doi: 10.1038/s41467-021-23233-6.
4
Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: A cross-sectional study.利用日本神户市门诊留存血清估计新型冠状病毒病(COVID-19)血清阳性率:一项横断面研究。
Clin Epidemiol Glob Health. 2021 Jul-Sep;11:100747. doi: 10.1016/j.cegh.2021.100747. Epub 2021 Apr 19.
5
Infection fatality rate of COVID-19 inferred from seroprevalence data.基于血清流行率数据推断的 COVID-19 感染病死率。
Bull World Health Organ. 2021 Jan 1;99(1):19-33F. doi: 10.2471/BLT.20.265892. Epub 2020 Oct 14.
6
Seroprevalence of antibodies to SARS-CoV-2 in healthcare workers & implications of infection control practice in India.印度医护人员中 SARS-CoV-2 抗体的血清阳性率及其对感染控制实践的影响。
Indian J Med Res. 2021;153(1 & 2):207-213. doi: 10.4103/ijmr.IJMR_3911_20.
7
How to detect and reduce potential sources of biases in studies of SARS-CoV-2 and COVID-19.如何发现和减少 SARS-CoV-2 和 COVID-19 研究中的潜在偏倚源。
Eur J Epidemiol. 2021 Feb;36(2):179-196. doi: 10.1007/s10654-021-00727-7. Epub 2021 Feb 25.
8
COVID-19 antibody seroprevalence in Santa Clara County, California.加利福尼亚州圣克拉拉县的新冠病毒抗体血清流行率。
Int J Epidemiol. 2021 May 17;50(2):410-419. doi: 10.1093/ije/dyab010.
9
SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic.英格兰在大流行首次高峰后 SARS-CoV-2 抗体流行率。
Nat Commun. 2021 Feb 10;12(1):905. doi: 10.1038/s41467-021-21237-w.
10
Seroprevalence and risk factors of exposure to COVID-19 in homeless people in Paris, France: a cross-sectional study.法国巴黎无家可归者中 COVID-19 的血清流行率和暴露风险因素:一项横断面研究。
Lancet Public Health. 2021 Apr;6(4):e202-e209. doi: 10.1016/S2468-2667(21)00001-3. Epub 2021 Feb 6.